Status:
UNKNOWN
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy
Lead Sponsor:
Sheba Medical Center
Conditions:
Leukemia, Myeloid, Philadelphia-Positive
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The study is controlled and randomized in Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients with complete cytogenetic response after more than one year of imatinib therapy. The aim is ...
Eligibility Criteria
Inclusion
- Ph+ CML patients in complete cytogenetic response (CCR) after more than 1 year of imatinib therapy.
Exclusion
- Patients in imatinib study
- Patients with a history of intolerability to interferon.
- Patients with less than CCR or less than one year of imatinib therapy.
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00297570
Start Date
February 1 2006
Last Update
October 10 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology, Sheba Medical Center
Tel Litwinsky, Tel-Hashomer, Israel, 52621